In 147 biologic-naïve adults with active ankylosing spondylitis, the MK2 inhibitor CC-99677 (60 or 150 mg daily) did not significantly improve week-12 ASAS20 response vs placebo (51.2%, 56.1% vs 48.8%); the trial stopped for futility at interim analysis.
RCTn = 147
Maksymowych et al. Phase II randomised, placebo-controlled study to evaluate the efficacy and safety of an MK2 inhibitor in ankylosing spondylitis